Iron supplementation and mortality in incident dialysis patients: An observational study

PLoS ONE

Volumn 9, Issue 12, 2014, Pages

  Zitt, Emanuel ^a,b   Sturm, Gisela ^c   Kronenberg, Florian ^c   Neyer, Ulrich ^b   Knoll, Florian ^a   Lhotta, Karl ^a,b   Weiss, Günter ^c  

^a Feldkirch Academic Teaching Hospital Vorarlberg Institute for Vascular Investigation and Treatment   (Austria)

^b Vorarlberg Institute for Vascular Investigation and Treatment VIVIT   (Austria)

^c INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIANEMIC AGENT; C REACTIVE PROTEIN; FERRIC GLUCONATE; FERRIC SULFATE; FERRITIN; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PLACEBO; RECOMBINANT ERYTHROPOIETIN; IRON;

ADULT; ANEMIA; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CAUSAL ATTRIBUTION; COHORT ANALYSIS; CONTROLLED STUDY; DRUG ADMINISTRATION ROUTE; FEMALE; FERRITIN BLOOD LEVEL; FOLLOW UP; GRAFT RECIPIENT; HEMODIALYSIS; HEMODIALYSIS PATIENT; HUMAN; INCIDENT DIALYSIS PATIENT; IRON THERAPY; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MORTALITY; OBSERVATIONAL STUDY; PERITONEAL DIALYSIS; PROTEIN BLOOD LEVEL; RISK REDUCTION; SEPSIS; SINGLE BLIND PROCEDURE; UPREGULATION; ADVERSE EFFECTS; AGED; RENAL REPLACEMENT THERAPY;

AGED; CARDIOVASCULAR DISEASES; COHORT STUDIES; FEMALE; HUMANS; IRON; MALE; MIDDLE AGED; RENAL DIALYSIS; SEPSIS;

EID: 84914692521     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0114144     Document Type: Article

References (57)

1. Koch KM, Bechstein PB, Fassbinder W, Kaltwasser P, Schoeppe W, et al. (1976) Occult blood loss and iron balance in chronic renal failure. Proc Eur Dial Transplant Assoc 12:362-369.
2. Lindsay RM, Burton JA, King P, Davidson JF, Boddy K, et al. (1973) The measurement of dialyzer blood loss. Clin Nephrol 1:24-28.
3. Goch J, Birgegard G, Danielson BG, Wikstrom B (1996) Iron absorption in patients with chronic uremia on maintenance hemodialysis and in healthy volunteers measured with a simple oral iron load test. Nephron 73:403-406.
4. Eschbach JW, Adamson JW (1999) Iron overload in renal failure patients: changes since the introduction of erythropoietin therapy. Kidney Int Suppl 69:S35-43.
5. Weiss G, Goodnough LT (2005) Anemia of chronic disease. N Engl J Med 352:1011-1023.
6. Carrera F, Lok CE, de Francisco A, Locatelli F, Mann JF, et al. (2010) Maintenance treatment of renal anaemia in haemodialysis patients with methoxy polyethylene glycol-epoetin beta versus darbepoetin alfa administered monthly: a randomized comparative trial. Nephrol Dial Transplant 25:4009-4017.
7. Deicher R, Horl WH (2003) Anaemia as a risk factor for the progression of chronic kidney disease. Curr Opin Nephrol Hypertens 12:139-143.
8. Macdougall IC (2008) Novel erythropoiesis-stimulating agents: a new era in anemia management. Clin J Am Soc Nephrol 3:200-207.
9. Goodnough LT, Nemeth E, Ganz T (2010) Detection, evaluation, and management of iron-restricted erythropoiesis. Blood 116:4754-4761.
10. Horl WH (2013) Anaemia management and mortality risk in chronic kidney disease. Nat Rev Nephrol 9:291-301.
11. Feldman HI, Santanna J, Guo W, Furst H, Franklin E, et al. (2002) Iron administration and clinical outcomes in hemodialysis patients. J Am Soc Nephrol 13: 734-744.
12. Kalantar-Zadeh K, Regidor DL, McAllister CJ, Michael B, Warnock DG (2005) Time-dependent associations between iron and mortality in hemodialysis patients. J Am Soc Nephrol 16: 3070-3080.
13. Feldman HI, Joffe M, Robinson B, Knauss J, Cizman B, et al. (2004) Administration of parenteral iron and mortality among hemodialysis patients. J Am Soc Nephrol 15:1623-1632.
14. Horl WH (2007) Clinical aspects of iron use in the anemia of kidney disease. J Am Soc Nephrol 18:382-393.
15. Nairz M, Schroll A, Sonnweber T, Weiss G (2010) The struggle for iron - a metal at the host-pathogen interface. Cell Microbiol 12:1691-1702.
16. Teehan GS, Bahdouch D, Ruthazer R, Balakrishnan VS, Snydman DR, et al. (2004) Iron storage indices: novel predictors of bacteremia in hemodialysis patients initiating intravenous iron therapy. Clin Infect Dis 38:1090-1094.
17. Vaziri ND (2013) Understanding iron: promoting its safe use in patients with chronic kidney failure treated by hemodialysis. Am J Kidney Dis 61:992-1000.
18. Litton E, Xiao J, Ho KM (2013) Safety and efficacy of intravenous iron therapy in reducing requirement for allogeneic blood transfusion: systematic review and meta-analysis of randomised clinical trials. BMJ 347:f4822.
19. Sturm G, Lamina C, Zitt E, Lhotta K, Lins F, et al. (2010) Sex-specific association of time-varying haemoglobin values with mortality in incident dialysis patients. Nephrol Dial Transplant 25:2715-2722.
20. Zitt E, Lamina C, Sturm G, Knoll F, Lins F, et al. (2011) Interaction of time-varying albumin and phosphorus on mortality in incident dialysis patients. Clin J Am Soc Nephrol 6:2650-2656.
21. Bailie GR, Larkina M, Goodkin DA, Li Y, Pisoni RL, et al. (2014) Data from the Dialysis Outcomes and Practice Patterns Study validate an association between high intravenous iron doses and mortality. Kidney Int doi: 10.1038/ki.2014.275. [Epub ahead of print].
22. Horl WH (2005) Anemia and its treatment in peritoneal dialysis patients. Wien Klin Wochenschr 117 Suppl 6:69-72.
23. Bailie GR, Larkina M, Goodkin DA, Li Y, Pisoni RL, et al. (2013) Variation in intravenous iron use internationally and over time: the Dialysis Outcomes and Practice Patterns Study (DOPPS). Nephrol Dial Transplant 28:2570-2579.
24. Koulouridis I, Alfayez M, Trikalinos TA, Balk EM, Jaber BL (2013) Dose of erythropoiesis-stimulating agents and adverse outcomes in CKD: a metaregression analysis. Am J Kidney Dis 61:44-56.
25. Szczech LA, Barnhart HX, Inrig JK, Reddan DN, Sapp S, et al. (2008) Secondary analysis of the CHOIR trial epoetin-alpha dose and achieved hemoglobin outcomes. Kidney Int 74:791-798.
26. Brookhart MA, Freburger JK, Ellis AR, Wang L, Winkelmayer WC, et al. (2013) Infection Risk with Bolus versus Maintenance Iron Supplementation in Hemodialysis Patients. J Am Soc Nephrol 24:1151-1158.
27. Kshirsagar AV, Freburger JK, Ellis AR, Wang L, Winkelmayer WC, et al. (2013) Intravenous iron supplementation practices and short-term risk of cardiovascular events in hemodialysis patients. PLoS One 8:e78930.
28. Macdougall IC, Geisser P (2013) Use of intravenous iron supplementation in chronic kidney disease: an update. Iran J Kidney Dis 7:9-22.
29. Fell LH, Zawada AM, Rogacev KS, Seiler S, Fliser D, et al. (2014) Distinct immunologic effects of different intravenous iron preparations on monocytes. Nephrol Dial Transplant 29:809-822.
30. Sonnweber T, Theurl I, Seifert M, Schroll A, Eder S, et al. (2011) Impact of iron treatment on immune effector function and cellular iron status of circulating monocytes in dialysis patients. Nephrol Dial Transplant 26:977-987.
31. Gupta A, Zhuo J, Zha J, Reddy S, Olp J, et al. (2010) Effect of different intravenous iron preparations on lymphocyte intracellular reactive oxygen species generation and subpopulation survival. BMC Nephrology 11:16-20.
32. Koskenkorva-Frank TS, Weiss G, Koppenol WH, Burckhardt S (2013) The complex interplay of iron metabolism, reactive oxygen species, and reactive nitrogen species: Insights into the potential of various iron therapies to induce oxidative and nitrosative stress. Free Radic Biol Med 65:1174-1194.
33. Weiss G, Kronenberg F (2014) Intravenous iron administration: new observations and time for the next steps. Kidney Int. In press.
34. Oexle H, Kaser A, Most J, Bellmann-Weiler R, Werner ER, et al. (2003) Pathways for the regulation of interferon-gamma-inducible genes by iron in human monocytic cells. J Leukoc Biol 74:287-294.
35. Weiss G, Meusburger E, Radacher G, Garimorth K, Neyer U, et al. (2003) Effect of iron treatment on circulating cytokine levels in ESRD patients receiving recombinant human erythropoietin. Kidney Int 64:572-578.
36. Kidney Disease: Improving Global Outcomes (KDIGO) Anemia Work Group (2012) KDIGO Clinical Practice Guideline for Anemia in Chronic Kidney Disease. Kidney Int., Suppl. 2:279-335.
37. Canavese C, Bergamo D, Ciccone G, Longo F, Fop F, et al. (2004) Validation of serum ferritin values by magnetic susceptometry in predicting iron overload in dialysis patients. Kidney Int 65:1091-1098.
38. Ferrari P, Kulkarni H, Dheda S, Betti S, Harrison C, et al. (2011) Serum iron markers are inadequate for guiding iron repletion in chronic kidney disease. Clin J Am Soc Nephrol 6:77-83.
39. Rostoker G, Griuncelli M, Loridon C, Couprie R, Benmaadi A, et al. (2012) Hemodialysis-associated hemosiderosis in the era of erythropoiesis-stimulating agents: a MRI study. Am J Med 125:991-999.
40. Knovich MA, Storey JA, Coffman LG, Torti SV, Torti FM (2009) Ferritin for the clinician. Blood Rev 23:95-104.
41. Thomas C, Thomas L (2005) Anemia of chronic disease: pathophysiology and laboratory diagnosis. Lab Hematol 11:14-23.
42. Meuwese CL, Snaedal S, Halbesma N, Stenvinkel P, Dekker FW, et al. (2011) Trimestral variations of C-reactive protein, interleukin-6 and tumour necrosis factor-alpha are similarly associated with survival in haemodialysis patients. Nephrol Dial Transplant 26:1313-1318.
43. Tovbin D, Mazor D, Vorobiov M, Chaimovitz C, Meyerstein N (2002) Induction of protein oxidation by intravenous iron in hemodialysis patients: role of inflammation. Am J Kidney Dis 40:1005-1012.
44. Brewster UC, Perazella MA (2004) Intravenous iron and the risk of infection in end-stage renal disease patients. Semin Dial 17:57-60.
45. Nairz M, Schleicher U, Schroll A, Sonnweber T, Theurl I, et al. (2013) Nitric oxide-mediated regulation of ferroportin-1 controls macrophage iron homeostasis and immune function in Salmonella infection. J Exp Med 210:855-87343.
46. van Asbeck BS, Marx JJ, Struyvenberg A, Verhoef J (1984) Functional defects in phagocytic cells from patients with iron overload. J Infect 8:232-240.
47. Sengoelge G, Kletzmayr J, Ferrara I, Perschl A, Horl WH, et al. (2003) Impairment of transendothelial leukocyte migration by iron complexes. J Am Soc Nephrol 14:2639-2644.
48. Patruta SI, Edlinger R, Sunder-Plassmann G, Horl WH (1998) Neutrophil impairment associated with iron therapy in hemodialysis patients with functional iron deficiency. J Am Soc Nephrol 9:655-663.
49. Deicher R, Ziai F, Cohen G, Mullner M, Horl WH (2003) High-dose parenteral iron sucrose depresses neutrophil intracellular killing capacity. Kidney Int 64:728-736.
50. Besarab A, Amin N, Ahsan M, Vogel SE, Zazuwa G, et al. (2000) Optimization of epoetin therapy with intravenous iron therapy in hemodialysis patients. J Am Soc Nephrol 11:530-538.
51. Kessler M, Hoen B, Mayeux D, Hestin D, Fontenaille C (1993) Bacteremia in patients on chronic hemodialysis. A multicenter prospective survey. Nephron 64:95-100.
52. Hoen B, Kessler M, Hestin D, Mayeux D (1995) Risk factors for bacterial infections in chronic haemodialysis adult patients: a multicentre prospective survey. Nephrol Dial Transplant 10:377-381.
53. Seifert A, von Herrath D, Schaefer K (1987) Iron overload, but not treatment with desferrioxamine favours the development of septicemia in patients on maintenance hemodialysis. Q J Med 65:1015-1024.
54. Tielemans CL, Lenclud CM, Wens R, Collart FE, Dratwa M (1989) Critical role of iron overload in the increased susceptibility of haemodialysis patients to bacterial infections. Beneficial effects of desferrioxamine. Nephrol Dial Transplant 4:883-887.
55. Boelaert JR, Daneels RF, Schurgers ML, Matthys EG, Gordts BZ, et al. (1990) Iron overload in haemodialysis patients increases the risk of bacteraemia: a prospective study. Nephrol Dial Transplant 5:130-134.
56. Hoen B, Paul-Dauphin A, Hestin D, Kessler M (1998) EPIBACDIAL: a multicenter prospective study of risk factors for bacteremia in chronic hemodialysis patients. J Am Soc Nephrol 9:869-876.
57. Stevens PE (2012) Anaemia, diabetes and chronic kidney disease: where are we now? J Ren Care 38 Suppl 1:67-77.